Novartis Entresto US patent upheld by US Court of Appeals
Basel: Novartis has announced that the Company is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto (sacubitril/valsartan) combination patent.
"We will work to appropriately enforce the combination patent through its pediatric exclusivity period expiring in July 2025," the Company stated.
"We will also continue to defend and protect all our important intellectual property and regulatory rights relating to Entresto," it added.
There are currently no generic versions of Entresto available in the US.
Formed in 1996, Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis was formed by the merger of Ciba-Geigy and Sandoz.
Read also: US Appeals Court decision favors MSN Pharma in Novartis heart drug Entresto generic dispute
